Viewing Study NCT07193160


Ignite Creation Date: 2025-12-25 @ 2:06 AM
Ignite Modification Date: 2025-12-26 @ 12:32 AM
Study NCT ID: NCT07193160
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-09-25
First Post: 2025-09-18
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
Sponsor: Fudan University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module